ClinicalTrials.gg
RecruitingNCT06420960WAHOEUpdated Sep 29, 2026

Diagnostic Efficacy of Connected WAtch ECG Versus External Holter ECG

An interventional study of Wearing the connected watch in Heart Disease, sponsored by L'hôpital Nord-Ouest - Villefranche Villefranche sur Saône. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by L'hôpital Nord-Ouest - Villefranche Villefranche sur Saône · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Sep 29, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
81
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 126 studies in Heart Diseases with a site in France — 29 open to participants now, 37 under way, 5 of them phase 3. Heart Diseases · France.

Planned enrollment
58th of 79
81 · median 240
Started
2025
with 6 others
No phase
48 of 126
9 open now
Primary completion
2027-01
later than 12 of 36 live
Registered
113th of 126
by date

Among the 126 studies in Heart Diseases with a site in France, this one is the 58th largest by planned enrollment of the 79 interventional ones that give a count, is one of 7 that started in 2025, is one of 48 with no phase, reaches primary completion later than 12 of the 36 other live ones, and was the 113th registered.

Heart Diseases

2,135 studies on the registry are indexed under Heart Diseases; 250 are open to participants now.

Browse Heart Diseases studies →

Open to participants now

29 of the 126 studies in Heart Diseases with a site in France are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 182 Heart Diseases studies recruiting now, 128 (70%) set no upper age limit and 22 (12%) stop at 75 or younger; 33 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies in Heart Diseases with a site in France, or all of them as a file.
02

Study summary

Palpitations are a frequent reason for consultation (16% of total volume) and management in the emergency department.

Conventional diagnostic management in our establishment is based on a 48-hour external ECG holter, combined with a stress test if symptoms are triggered by physical activity.

The diagnostic difficulty lies in the frequency and duration of this transient symptom. At the time of consultation, the patient is often asymptomatic. The initial strategy is to demonstrate an electrocardiographic trace during the attack, in order to adapt management to the chosen etiology.

The HOLTER ECG is the gold standard, but it is not very cost-effective due to the infrequent and random nature of the onset of symptoms.

The advent of accessible connected tools such as connected watches seems to be an interesting alternative for acquiring a per-critical trace of symptoms. They are widely adopted by the general population, with ease of use by the individual and long monitoring times.

The main aim of the study is to establish the diagnostic cost-effectiveness of one or other of the two diagnostic strategies (rate of identification of the causal arrhythmia) at 6 months from the cardiological consultation.

03

Conditions studied

  • Heart Disease

Browse trials for

Keywords

  • palpitations
  • yield diagnostic
  • connected watch
  • device
  • HOLTER ECG
  • monitoring
  • profitability
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any patient consulting for the main reason of palpitations; without a previous diagnosis of arrhythmia, unless the current symptomatology appears different from that associated with the previous rythmological diagnosis;
  • Palpitations requiring cardiological consultation or emergency hospital treatment;
  • Absence of suggestive diagnosis on intercritical 12-lead (pre-excitation, AVB M2/3, high-grade atrioventricular block, non-sustained tachyventricular, atrial fibrillation with heart rate; 110 per minute, atrial tachycardia or flutter);
  • Non-contributory stress test (no electrical abnormality, occurrence of arrhythmia or reproduction of palpitations) if isymptoms occur during exercise;
  • Accepts to wear the watch all the time outside the charging time;
  • Using a personal smartphone or tablet compatible with the Health Mate application and with an Internet connection;
  • Affiliated with a social security system ;
  • Providing dated and signed an form.

Exclusion criteria

Exclusion Criteria:

  • Refusal to wear the connected watch;
  • Refusal to use the watch provided for the study because they use a personal connected watch;
  • Unable to use the connected watch (lack of understanding of its use and rationale);
  • No smartphone;
  • Wearer of an implantable device (PM, ICD);
  • Already known and treated arrhythmia with identical symptoms;
  • Heart disease with indication for primary/secondary prevention implantable device;
  • Associated syncope;
  • Obvious extra-cardiac cause;
  • Pregnant or breast-feeding woman;
  • Inability to undergo study follow-up for geographical, linguistic, social or psychological reasons;
  • Participating in another clinical study which can interfere with this study
  • Patient under guardianship or deprived of liberty.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
81 participants (estimated)

Study arms

  • Experimental
    connected watch

    All patients will be equipped by HOLTER for 48-hour monitoring, with an event form to be filled in, at the same time as receiving a connected watch for a 6 -months period. They will be asked to record an ECG with the watch only when they experience symptoms that have included them in the study

    Device: Wearing the connected watch

  • Active comparator
    HOLTER ECG 48 hours

    All patients will be equipped by HOLTER for 48-hour monitoring, with an event form to be filled in, at the same time as receiving a connected watch for a 6 -months period. They will be asked to record an ECG with the watch only when they experience symptoms that have included them in the study

    Device: Wearing the connected watch

Interventions

  • DeviceWearing the connected watch

    All patients will receive a connected watch from the research associate, along with instructions on its usage and support for creating an account on the Healtmate application using an anonymized e-mail address. They will be able to transmit up to 3 ECG tracings deemed to be per-critical. A follow-up phone call at 2- months will assess understanding of the device and its proper use, as well as the occurrence of adverse events and compliance.

06

What researchers measure

Primary outcomes

  1. Rate of diagnostic profitability of the connected watch compared with the conventional procedure (48-hour ECG Holter).

    The investigators will compare the diagnostic performance of the connected watch with the HOLTER ECG, by identifying a symptomatic arrhythmia, , in the purpose of a faster and adapted cardiological management.

    Time frame: at 6 months or when the watch is returned, whether a diagnosis has been made or whether there have been 3 ECG transmissions that did not reveal any cardiac arrhythmia.

Secondary outcomes

  1. Type of diagnosis recorded.

    A diagnosis is defined by the documentation of an objective cardiac arrhythmia (focal atrial tachycardia/atrial fibrillation HR \>110 bpm/atrial fibrillation HR\<110 bpm/atrial flutter/junctional tachycardia/sustained or non-sustained ventricular tachycardia/peak tachycardia/sinus tachycardia/ventricular fibrillation/high-degree conduction disorder) concomitant with the symptomatology motivating the initial consultation.

    Time frame: at 6 months or when the watch is returned if a diagnosis has been made.

  2. Rate of concomitant diagnoses with either device

    Symptomatic objective cardiac arrythmia recorded with the smarwatch, the HOLTER or the both

    Time frame: at 6 months or when the watch is returned if a diagnosis has been made.

  3. Rate of causal non-rhythmological diagnosis (symptoms without pathological per-critical ECG tracing)

    Rate of ECGs failing to explain symptomatology (no ECG abnormality detected ECG) Time Frame : at 6 months or when the watch is returned if a diagnosis has been made or if there have been 3 ECG transmissions that did not reveal any cardiac arrhythmia.

    Time frame: at 6 months or when the watch is returned if a diagnosis has been made or if there have been 3 ECG transmissions that did not reveal any cardiac arrhythmia.

  4. Medical/paramedical time per diagnosis and per patient

    Fitting of holter ECG equipment, handover of watch and explanation of how it works, analysis of holter/ ECG tracings, reconsultation)

    Time frame: at 6 months or when the watch is returned, whether a diagnosis has been made or whether there have been 3 ECG transmissions that did not reveal any cardiac arrhythmia.

07

Study locations

1 of 1 sites recruiting
  • Hopitaux Nord-Ouest Villefranche Sur Saone
    Gleizé, 69400, France
    Recruiting
    • COLINE PERRIER, ARC · Contactrecherche@hno.fr · 0474092473
    • OLIVIER LE VAVASSEUR, MEDECINE · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided — Confidentiality and Privacy: Sharing IPD data could compromise the confidentiality and privacy of participants. Individual data, even anonymized, could potentially be used to identify individuals, particularly in the case of small cohorts or sensitive data. Data Sensitivity: IPD data includes sensitive health information. Sharing such data is subject to strict data protection regulations and requires additional measures to ensure security and confidentiality. Resources and Costs: Sharing IPD data requires additional resources for anonymization, management, and data provision. We do not have the necessary resources to perform these tasks due to our limited budget.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jan 2027, 21 months after the start.

Of 264 non-industry interventional studies with no phase under Heart Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 21 months is below that.

Counting every sponsor, half of 337 studies reached it within 25 months; a quarter within 11 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2024
First posted
May 20, 2024
StartActual
Apr 15, 2025
Primary completionEst.
Jan 18, 2027
CompletionEst.
Feb 17, 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Hopitaux Nord-Ouest Villefranche Sur Saone · Gleizé, France
Show 1 removed
  • Hopitaux Nord-Ouest Villefranche Sur Saone · Gleize, France
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    1 site added, 1 site removed
    Show site
    • Hopitaux Nord-Ouest Villefranche Sur Saone · Gleizé, France
    Show 1 removed
    • Hopitaux Nord-Ouest Villefranche Sur Saone · Gleize, France
    + 4 other changes: verification date, date precision, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06420960
Lead sponsor
L'hôpital Nord-Ouest - Villefranche Villefranche sur Saône
Responsible party
Sponsor
First posted
May 20, 2024
Start date
Apr 15, 2025
Primary completion
Jan 18, 2027 (estimated)
Completion
Feb 17, 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

OLIVIER LE VAVASSEUR, MEDECINE
Contact
olevavasseur@hno.fr
0474092753 ext. +33
COLINE PERRIER, ARC
Contact
cperrier@hno.fr
0474092473 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion